JT PHARMACEUTICALS, INC.
Biotech · Defunct
Neurotensin receptor 1 (NTR1) agonist small-molecule drugs that induce pharmacological hypothermia for neuroprotection in stroke and traumatic brain injury
- Grants
- $5.6M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of a Neurotensin Fragment for Neuropathic Pain | $647,660 | |
| Federal grant | Department of Health and Human Services · Phase II · Stroke Treatment by Chemically-induced Hypothermia | $793,793 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Neurotensin Fragment for Neuropathic Pain | $599,575 | |
| Federal grant | Department of Health and Human Services · Phase II · Stroke Treatment by Chemically-induced Hypothermia | $706,207 | |
| Federal grant | Department of Health and Human Services · Phase II · Stroke Treatment by Chemically-induced Hypothermia | $965,517 | |
| Federal grant | Department of Health and Human Services · Phase II · Stroke Treatment by Chemically-induced Hypothermia | $965,515 | |
| Federal grant | Department of Health and Human Services · Phase II · Stroke Treatment by Chemically-induced Hypothermia | $965,517 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1331 | Knudra Diagnostics | — | — |
| 1332 | NURAVAX, INC. | — | — |
| 1333 | LEUKOSIGHT, INC. | — | — |
| 1334 | JT PHARMACEUTICALS, INC. | — | — |
| 1335 | YUMA THERAPEUTICS CORPORATION | — | — |
| 1336 | MINUTIA INC | — | — |
| 1337 | AVERY BIO CORPORATION | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Sustained Release Compositions Of Kappa-opioid Receptor Agonistapplication
- Sustained Release Compositions Of Kappa-opioid Receptor Agonistapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.